Can I Take Green Tea Extract (EGCG) with Repatha (Evolocumab)?

How Repatha Works and Why Its Metabolism Matters

Evolocumab is a fully human monoclonal antibody that binds and inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab allows LDL receptors to recycle, pulling more LDL-C from circulation. In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks reduced LDL-C by 59% from baseline and cut the composite cardiovascular endpoint by 15% versus placebo over a median of 2.2 years [1].

Evolocumab Is Not a CYP Substrate

Unlike statins, fibrates, or many small-molecule lipid drugs, evolocumab is a large-protein biologic. It is catabolized through proteolytic degradation pathways common to all endogenous IgG antibodies, not through hepatic CYP450 enzymes [2]. This distinction matters enormously when assessing supplement interactions.

Because CYP1A2, CYP3A4, and CYP2C9 are not involved in evolocumab clearance, any compound that inhibits or induces those enzymes, including EGCG, cannot alter evolocumab plasma concentrations through pharmacokinetic mechanisms. A pharmacokinetic drug-supplement interaction between green tea extract and evolocumab is not expected based on current mechanistic data [3].

What the FDA Label Does and Does Not Say

The Repatha prescribing information approved by the FDA does not list any supplement interactions and does not identify drug-drug interactions mediated by CYP enzymes [2]. That label silence is not a green light for unrestricted supplementation. It simply means the pharmacokinetic pathway is clean. The hazard shifts entirely to what the supplement does on its own, independent of evolocumab.

What EGCG Does in the Body

EGCG (epigallocatechin-3-gallate) is the predominant catechin in green tea extract. A single 200 mg capsule of a standardized 50% EGCG extract delivers roughly 100 mg of EGCG, while one 250 mL cup of brewed green tea delivers approximately 50-100 mg [4].

Antioxidant and LDL Effects

EGCG has modest LDL-lowering activity in its own right. A 2020 meta-analysis of 31 randomized controlled trials (N=3,321) found green tea catechins reduced LDL-C by a mean of 4.54 mg/dL (95% CI: 2.01-7.07 mg/dL, P<0.001) [5]. That effect size is small compared with the 59% LDL reduction from evolocumab, so combining the two for additive LDL lowering is not a compelling clinical rationale. The more pressing question is safety.

CYP Enzyme Inhibition by EGCG

EGCG does inhibit CYP1A2 and, to a lesser extent, CYP2C9 and CYP3A4 in in-vitro studies [6]. In practice, those inhibition effects are clinically relevant only for drugs cleared by those pathways. Because evolocumab avoids CYP metabolism entirely, EGCG's enzyme-inhibition properties are irrelevant to evolocumab plasma levels. They may, however, affect co-administered medications such as warfarin (CYP2C9), certain beta-blockers (CYP1A2), or immunosuppressants (CYP3A4) in patients taking those drugs alongside Repatha.

The Real Risk: EGCG-Induced Hepatotoxicity

This is where clinical caution is genuinely warranted. High-dose green tea extract is one of the most commonly implicated herbal supplements in drug-induced liver injury (DILI) case reports.

Regulatory Warnings and Case Data

The European Food Safety Authority (EFSA) published a 2018 opinion concluding that EGCG doses at or above 800 mg/day are associated with signs of liver toxicity, and that 338 mg EGCG/day represents a safe upper threshold for the general population [7]. The U.S. Pharmacopeia's Dietary Supplement Information Expert Committee issued a cautionary monograph on green tea extract after reviewing 216 case reports of liver toxicity, including cases requiring transplantation [8].

In the NIH LiverTox database, green tea extract is classified as a "likely" cause of clinically apparent liver injury, with a typical latency of 1-3 months after starting supplementation [9].

Why This Matters for Repatha Patients Specifically

Evolocumab itself has an extremely favorable hepatic safety profile. In the FOURIER trial, liver enzyme elevations greater than three times the upper limit of normal occurred in less than 1% of participants in both the evolocumab and placebo groups [1]. Repatha does not cause hepatotoxicity on its own at therapeutic doses.

The concern is additive hepatic stress. Many patients prescribed evolocumab are already taking high-intensity statins such as rosuvastatin 40 mg or atorvastatin 80 mg. Statins carry their own low but real risk of transaminase elevation. Layering a high-dose EGCG supplement onto statin therapy and evolocumab introduces a third hepatic insult that, in susceptible individuals, could push liver enzymes into clinically significant territory.

Dose Is the Deciding Variable

The risk picture separates cleanly by dose:

| EGCG Source | Approximate EGCG Per Day | Hepatotoxicity Signal | |---|---|---| | Brewed green tea, 2-3 cups | 100-300 mg | None in population studies | | Low-dose extract, 200-400 mg EGCG | 200-400 mg | Rare; below EFSA safe threshold | | High-dose extract, 800 mg+ EGCG | 800+ mg | Associated with DILI case reports |

Patients who drink brewed green tea have not been associated with liver injury in epidemiological cohorts, likely because absorption of EGCG from brewed tea is slower and the total dose is lower than from fasted-state bolus supplementation [7].

Pharmacodynamic Considerations

Beyond the liver, there are a few secondary pharmacodynamic points worth understanding.

Antiplatelet Activity

EGCG inhibits platelet aggregation through thromboxane A2 pathway modulation [10]. Evolocumab has no direct antiplatelet effect. For most patients this interaction is inconsequential, but for patients also taking aspirin, clopidogrel, or anticoagulants, cumulative antiplatelet burden warrants a conversation with the prescribing clinician before starting green tea extract supplements.

Blood Pressure Effects

High-dose EGCG may produce a modest reduction in systolic blood pressure. A 2014 meta-analysis (N=1,006) found green tea catechins reduced systolic BP by 2.1 mmHg and diastolic BP by 1.7 mmHg [11]. For patients with ASCVD already managed with antihypertensive drugs, this is generally additive in a beneficial direction. No documented interaction with evolocumab's mechanism exists in this domain.

Iron Absorption Interference

EGCG chelates non-heme iron and can reduce iron absorption by up to 25% when taken with iron-containing meals [12]. This is unrelated to evolocumab pharmacology but is relevant to any patient taking iron supplementation concurrently.

Monitoring Protocol If You Are Already Taking Both

Some patients arrive at their telehealth consultation already combining Repatha with a green tea extract supplement they purchased before starting the biologic. The following framework guides clinical assessment:

Step 1: Establish Baseline Liver Function

Order ALT and AST before continuing the supplement. If baseline values are already above the upper limit of normal, green tea extract supplementation at any dose above 200 mg EGCG/day should be discontinued until enzymes normalize.

Step 2: Characterize the Dose

Ask for the product label. Look for mg of EGCG per serving, not total catechins or total green tea extract weight. Products listing only "green tea extract 500 mg" without specifying EGCG content are harder to dose-assess; err toward caution with those.

Step 3: Set a Recheck Timeline

If the patient continues the supplement at a dose below 338 mg EGCG/day, repeat ALT and AST at 6-8 weeks. The NIH LiverTox latency data shows most EGCG-related DILI presents within 1-3 months of starting [9], so a 6-8 week check catches the early window.

Step 4: Apply the Stop Rule

If ALT rises above three times the upper limit of normal on two consecutive measurements, the supplement should stop immediately. Re-checking LFTs 4-6 weeks after discontinuation confirms resolution and rules out other causes.

What the Guidelines Say About PCSK9 Inhibitors and Supplements

The 2022 ACC/AHA Guideline on the Management of Atherosclerotic Cardiovascular Disease does not directly address herbal supplement co-administration with PCSK9 inhibitors [13]. The guideline notes that evolocumab is the preferred add-on therapy for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, but says nothing about concurrent supplementation.

The American College of Cardiology's CardioSmart patient resource acknowledges that supplements can affect liver enzymes but defers specific interaction guidance to the prescribing physician [14]. That deference reflects the reality that supplement-biologic interaction data from controlled trials is almost entirely absent from the published literature as of mid-2025.

The 2023 National Lipid Association Statin Safety and PCSK9 Inhibitor Consensus does state: "Patients should disclose all dietary supplements to their lipid specialist, as some supplements may affect hepatic safety monitoring thresholds and confound interpretation of transaminase elevations." [15]

Green Tea Beverages vs. Supplements: A Critical Distinction

Brewed green tea and green tea extract capsules are not clinically equivalent. This distinction appears repeatedly in the hepatotoxicity literature and warrants clear patient communication.

A 250 mL cup of brewed green tea contains approximately 50-100 mg of EGCG depending on brew time and leaf variety [4]. To reach the 800 mg EGCG threshold EFSA associates with hepatotoxicity, a patient would need to drink 8-16 cups per day. No population cohort has linked habitual tea drinking at 2-4 cups per day with liver injury.

Concentrated capsule supplements bypass the gradual absorption kinetics of brewed tea. EGCG from capsules taken in a fasted state reaches peak plasma concentration faster and at higher Cmax than the same EGCG consumed in beverage form [7]. The faster absorption profile is the likely explanation for why case reports cluster around supplement use, not tea drinking.

Patients who ask "can I drink green tea while on Repatha?" should receive a straightforward answer: yes, at typical consumption levels of 2-4 cups per day, brewed green tea poses no identified risk in the context of evolocumab therapy. The question becomes more complex when concentrated extracts are involved.

Practical Guidance for Patients and Clinicians

For patients who want the antioxidant or modest LDL benefits attributed to green tea catechins, beverage consumption of 2-3 cups per day is a reasonable, low-risk approach that avoids the hepatotoxicity signal entirely.

For patients already using high-dose green tea extract supplements (above 400 mg EGCG/day), the steps are:

1. Tell your Repatha prescriber before your next injection refill.
2. Get baseline liver function tests if you have not had them in the past 3 months.
3. Consider switching to brewed green tea or a low-dose extract below 200 mg EGCG/day.
4. Re-check ALT and AST at 6-8 weeks if you continue any extract supplement.

For clinicians, the absence of a pharmacokinetic interaction does not mean the combination is automatically safe. Evolocumab's clean hepatic profile could be obscured by EGCG-related transaminase elevation, complicating attribution if liver values rise. Clear documentation of supplement use in the chart protects the patient and the clinician.

Co-Therapy Complexity: Statins, Evolocumab, and EGCG Together

Most patients prescribed evolocumab are simultaneously on a high-intensity statin. That three-way combination is worth addressing explicitly.

Rosuvastatin is primarily a CYP2C9 substrate. EGCG's mild CYP2C9 inhibitory activity in vitro has not been shown to produce clinically meaningful rosuvastatin exposure increases in human pharmacokinetic studies at standard supplement doses [6]. Atorvastatin is primarily a CYP3A4 substrate; similar reasoning applies.

The more relevant statin concern is additive hepatic stress. Both statins and high-dose EGCG can independently raise transaminases. A patient on atorvastatin 80 mg plus a 1,000 mg EGCG green tea extract supplement plus evolocumab is presenting three simultaneous hepatic exposures. If ALT rises in that context, distinguishing the causative agent is difficult without sequential elimination. Starting supplementation one variable at a time, when possible, simplifies that attribution problem.